An Open Letter to the Food and Drug Administration and Pharmaceutical Industry Concerning Drug Approval for Children With Inflammatory Bowel Disease
Jeffrey S. Hyams(Connecticut Children's Medical Center), Eric J. Zückerman, Andrew E. Mulberg, Harland S. Winter(Massachusetts General Hospital)
Cited by 3
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k